AIDS Vaccine Developer HIV-VAC, Inc. Featured On Top Rated Investor Relations Internet Site: Stockprofiles.com.

TORONTO--(BUSINESS WIRE)--May 19, 1999--

HIV-VAC, Inc., (OTC BB:HIVC) announced today that the company has been selected to be featured on one of the top-rated investor relations Internet web sites: www.stockprofiles.com/hivc

This HIV vaccine was originally developed by Dr. Gordon Skinner, MD (Hons), DSc, FRCOG, FRCPath at the University of Birmingham, UK. It has been under development by Dr. Skinner for the last 10 years and toxicity trials are almost completed. Phase one and two trials will begin soon.

Dr. Skinner said, "Not only is the vaccine expected to prevent the disease, but it also may prevent the onset of AIDS in HIV positive patients. Many scientists have been working on a vaccine for AIDS over the last 10 years. Most of these studies have developed traditional approaches using old technology that have produced little in the hope for a vaccine to successfully battle the AIDS virus. We have developed a brand new approach to the AIDS problem through the creation of an intracellular vaccine that is based on a technology proven in clinical trials with both herpes genitalis and pre-clinical research into cytomegalovirus and equine herpes vaccines."

Clinical trials with the HIV-VAC vaccine will be underway within nine months, with completion of studies and Government approvals within two to three years. Other companies currently, or soon to become involved, in phase three trials with HIV vaccines based on traditional technologies include Warner Lambert (NYSE:WLA), Cytogen Corporation (Nasdaq:CYTO), Immune Response Corp. (Nasdaq:IMNR), Neogen Corp. (Nasdaq:NEOG) and CEL-SCI Corp. (AMEX:HIV).

The United Nations estimates that there are currently 30.6 million people infected worldwide with the AIDS virus. The disease is spreading at a rate of 10,000 people each day. It is estimated that the number of people infected with the AIDS virus by the end of the year 2000 will be 55 million.

Lou Andrenna, Chief Executive Officer for Hastings Communications said, "HIV-VAC, Inc. will be able to enhance the growth of their public company by providing corporate information, financials and development updates to the professional financial community and the individual investors who use our site."

"For a company like HIV-VAC to grow successfully in today's marketplace," Andrenna added, "they must cultivate strong public awareness and market recognition. Hastings Communications and www.stockprofiles.com plan to do that for HIV-VAC via the Internet."

With over 600,000 investor hits per month and no user fee, www.stockprofiles.com is an investor relations Internet site designed for public companies to distribute their annual reports, corporate profiles, financials, SEC filings and press/news releases to the professional investment community and the individual investor by providing the visitors to www.stockprofiles.com with single site access for all the information they need to make efficient and effective investment decisions.

The statements contained in this release which are not historical facts contain forward-looking information with respect to plans, projections or future performance of the company; the occurrence of which involves certain risks and uncertainties that could cause the company's actual results to differ materially from expected results. Such risks include the timing of implementation and the scope and success of the program described here.

For more information: K. Jelsing, Investor Relations: Toll Free 877/778-7731.

For Live Interview: www.wallstreetinterview.com